Drug Approval | January 05, 2025
CDSCO approves Wockhardt’s Mignaf for treatment of community acquired bacterial pneumonia
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
Subscribe To Our Newsletter & Stay Updated
